Kim, TaeHun Yang, Ha Yun Park, Beoung Gun Jung, Seo Yun Park, Jong-Hyun Park, Ki Duk Min, Sun-Joon Tae, Jinsung Yang, Hyejin Cho, Suengmok Cho, Sung Jin Song, Hyundong Mook-Jung, Inhee Lee, Jiyoun Pae, Ae Nim 2024-01-20T02:31:52Z 2024-01-20T02:31:52Z 2021-09-04 2017-01-05 0223-5234 https://pubs.kist.re.kr/handle/201004/123219 In this study, we designed a library of compounds based on the structures of well-known ligands of the 18 kDa translocator protein (TSPO), one of the putative components of the mPTP. We performed diverse mitochondrial functional assays to assess their ability to restore cells from A beta-induced toxicity in vitro and in vivo. Among tested compounds, compound 25 effectively improved cognitive function in animal models of AD. Given the excellent in vitro and in vivo activity and a favorable pharmacokinetic profile of compound 25, we believe that it can serve as a promising lead compound for a potential treatment option for AD. (C) 2016 Elsevier Masson SAS. All rights reserved. English ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PERMEABILITY TRANSITION PORE AMYLOID-BETA CYCLOPHILIN-D A-BETA INHIBITOR TSPO REPERFUSION DYSFUNCTION HYPOTHESIS DIAGNOSIS Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease Article 10.1016/j.ejmech.2016.11.017 1 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.125, pp.1172 - 1192 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 125 1172 1192 scie scopus 000390496600094 2-s2.0-84995688336 Chemistry, Medicinal Pharmacology & Pharmacy Article PERMEABILITY TRANSITION PORE AMYLOID-BETA CYCLOPHILIN-D A-BETA INHIBITOR TSPO REPERFUSION DYSFUNCTION HYPOTHESIS DIAGNOSIS Translocator protein TSPO Mitochondrial permeability transition pore Alzheimer&apos s disease Mitochondrial dysfunction A beta